Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems
Background: In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosin...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes science and technology 2017-09, Vol.11 (5), p.970-974 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 974 |
|---|---|
| container_issue | 5 |
| container_start_page | 970 |
| container_title | Journal of diabetes science and technology |
| container_volume | 11 |
| creator | Pardo, Scott Dunne, Nancy Simmons, David A. |
| description | Background:
In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosing errors were compared for each trial.
Method:
For each blood glucose measurement, premeal bolus insulin dosing was determined for a hypothetical person, assuming a 60-g carbohydrate meal and 100-mg/dL target blood glucose level (adjusting 1/25 insulin sensitivity and 1/15 insulin:carbohydrate ratio inputs to account for BGMS measurement error). Dosing error was the difference between doses calculated using the BGMS and YSI results.
Results:
In Clinical Trial 1, 95% dose error ranges (in units of insulin) were: CONTOUR®NEXT EZ BGMS (EZ), –0.9 to 0.5; Accu-Chek® Aviva BGMS (ACA), –0.5 to 1.8; FreeStyle Freedom Lite® BGMS (FFL), –3.2 to −0.3; OneTouch® Ultra®2 BGMS (OTU2), –4.1 to 0.3; and Truetrack® BGMS (TT), –3.9 to 2.2. In Clinical Trial 2, these ranges were: CONTOUR®NEXT BGMS (CN), –0.7 to 1.7; Accu-Chek® Aviva Nano BGMS (ACAN), –1.3 to 1.8; FreeStyle Lite® BGMS (FSL), –5.1 to 0.2; OTU2, –1.9 to 1.2; OneTouch® Verio® Pro BGMS (OTVP), –1.0 to 1.9; and TT, –5.1 to 1.7. Within each trial, EZ and CN had statistically significantly smaller insulin dose error ranges than other BGMSs (P |
| doi_str_mv | 10.1177/1932296817713025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5950998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1932296817713025</sage_id><sourcerecordid>1908794630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3495-bb12416acc407ab25f7963eb440014baebb84e0621a19bd976ca58acb85942163</originalsourceid><addsrcrecordid>eNp1kUFvEzEQhS0EoqVw7wn5yGXB3vV61xckkrSlUhFSCWfLdpzUldeTenaLKv48TlOqUonTjGbe-2zNI-SYs4-cd90nrpq6VrIvPW9Y3b4gh7tRtZu9fNIfkDeI14y1ou-61-Sg7iUTTIpD8nsGcUJ6nnCKIdEFoKcnOUOmi4BjDnYaAySkM4N-RSHRS1-UI9LTDANd_gI6L77gTKTLHExEOodha3JIGzqLACt6Fie3o36DFEa4X_y4w9EP-Ja8WheHf_dQj8jP05Pl_Gt18f3sfP7lonKNUG1lLa8Fl8Y5wTpj63bdKdl4KwRjXFjjre2FZ7Lmhiu7Up10pu2Ns32rRM1lc0Q-77nbyQ5-5Xwas4l6m8Ng8p0GE_S_mxSu9AZudataplRfAB8eABluJo-jHgI6H6NJHibUXLG-U0I2rEjZXuoyIGa_fnyGM73LTD_PrFjeP_3eo-FvSEVQ7QVoNl5fw5RTOdf_gX8AZF2gyw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1908794630</pqid></control><display><type>article</type><title>Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems</title><source>Access via SAGE</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pardo, Scott ; Dunne, Nancy ; Simmons, David A.</creator><creatorcontrib>Pardo, Scott ; Dunne, Nancy ; Simmons, David A.</creatorcontrib><description>Background:
In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosing errors were compared for each trial.
Method:
For each blood glucose measurement, premeal bolus insulin dosing was determined for a hypothetical person, assuming a 60-g carbohydrate meal and 100-mg/dL target blood glucose level (adjusting 1/25 insulin sensitivity and 1/15 insulin:carbohydrate ratio inputs to account for BGMS measurement error). Dosing error was the difference between doses calculated using the BGMS and YSI results.
Results:
In Clinical Trial 1, 95% dose error ranges (in units of insulin) were: CONTOUR®NEXT EZ BGMS (EZ), –0.9 to 0.5; Accu-Chek® Aviva BGMS (ACA), –0.5 to 1.8; FreeStyle Freedom Lite® BGMS (FFL), –3.2 to −0.3; OneTouch® Ultra®2 BGMS (OTU2), –4.1 to 0.3; and Truetrack® BGMS (TT), –3.9 to 2.2. In Clinical Trial 2, these ranges were: CONTOUR®NEXT BGMS (CN), –0.7 to 1.7; Accu-Chek® Aviva Nano BGMS (ACAN), –1.3 to 1.8; FreeStyle Lite® BGMS (FSL), –5.1 to 0.2; OTU2, –1.9 to 1.2; OneTouch® Verio® Pro BGMS (OTVP), –1.0 to 1.9; and TT, –5.1 to 1.7. Within each trial, EZ and CN had statistically significantly smaller insulin dose error ranges than other BGMSs (P <0.0001).
Conclusions:
The ranges of insulin dose errors were statistically significantly smaller with EZ and CN than with all other BGMSs in this post hoc analysis. Differences in BGMS accuracy could result in clinically important differences in insulin dosing.</description><identifier>ISSN: 1932-2968</identifier><identifier>EISSN: 1932-2968</identifier><identifier>EISSN: 1932-3107</identifier><identifier>DOI: 10.1177/1932296817713025</identifier><identifier>PMID: 28604064</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Blood Glucose Self-Monitoring - adverse effects ; Blood Glucose Self-Monitoring - methods ; Clinical Trials as Topic ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 2 - blood ; Humans ; Hypoglycemic Agents - administration & dosage ; Insulin - administration & dosage ; Medication Errors - statistics & numerical data ; Original</subject><ispartof>Journal of diabetes science and technology, 2017-09, Vol.11 (5), p.970-974</ispartof><rights>2017 Diabetes Technology Society</rights><rights>2017 Diabetes Technology Society 2017 Diabetes Technology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3495-bb12416acc407ab25f7963eb440014baebb84e0621a19bd976ca58acb85942163</citedby><cites>FETCH-LOGICAL-c3495-bb12416acc407ab25f7963eb440014baebb84e0621a19bd976ca58acb85942163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950998/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950998/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,21819,27924,27925,43621,43622,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28604064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pardo, Scott</creatorcontrib><creatorcontrib>Dunne, Nancy</creatorcontrib><creatorcontrib>Simmons, David A.</creatorcontrib><title>Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems</title><title>Journal of diabetes science and technology</title><addtitle>J Diabetes Sci Technol</addtitle><description>Background:
In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosing errors were compared for each trial.
Method:
For each blood glucose measurement, premeal bolus insulin dosing was determined for a hypothetical person, assuming a 60-g carbohydrate meal and 100-mg/dL target blood glucose level (adjusting 1/25 insulin sensitivity and 1/15 insulin:carbohydrate ratio inputs to account for BGMS measurement error). Dosing error was the difference between doses calculated using the BGMS and YSI results.
Results:
In Clinical Trial 1, 95% dose error ranges (in units of insulin) were: CONTOUR®NEXT EZ BGMS (EZ), –0.9 to 0.5; Accu-Chek® Aviva BGMS (ACA), –0.5 to 1.8; FreeStyle Freedom Lite® BGMS (FFL), –3.2 to −0.3; OneTouch® Ultra®2 BGMS (OTU2), –4.1 to 0.3; and Truetrack® BGMS (TT), –3.9 to 2.2. In Clinical Trial 2, these ranges were: CONTOUR®NEXT BGMS (CN), –0.7 to 1.7; Accu-Chek® Aviva Nano BGMS (ACAN), –1.3 to 1.8; FreeStyle Lite® BGMS (FSL), –5.1 to 0.2; OTU2, –1.9 to 1.2; OneTouch® Verio® Pro BGMS (OTVP), –1.0 to 1.9; and TT, –5.1 to 1.7. Within each trial, EZ and CN had statistically significantly smaller insulin dose error ranges than other BGMSs (P <0.0001).
Conclusions:
The ranges of insulin dose errors were statistically significantly smaller with EZ and CN than with all other BGMSs in this post hoc analysis. Differences in BGMS accuracy could result in clinically important differences in insulin dosing.</description><subject>Blood Glucose Self-Monitoring - adverse effects</subject><subject>Blood Glucose Self-Monitoring - methods</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Insulin - administration & dosage</subject><subject>Medication Errors - statistics & numerical data</subject><subject>Original</subject><issn>1932-2968</issn><issn>1932-2968</issn><issn>1932-3107</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFvEzEQhS0EoqVw7wn5yGXB3vV61xckkrSlUhFSCWfLdpzUldeTenaLKv48TlOqUonTjGbe-2zNI-SYs4-cd90nrpq6VrIvPW9Y3b4gh7tRtZu9fNIfkDeI14y1ou-61-Sg7iUTTIpD8nsGcUJ6nnCKIdEFoKcnOUOmi4BjDnYaAySkM4N-RSHRS1-UI9LTDANd_gI6L77gTKTLHExEOodha3JIGzqLACt6Fie3o36DFEa4X_y4w9EP-Ja8WheHf_dQj8jP05Pl_Gt18f3sfP7lonKNUG1lLa8Fl8Y5wTpj63bdKdl4KwRjXFjjre2FZ7Lmhiu7Up10pu2Ns32rRM1lc0Q-77nbyQ5-5Xwas4l6m8Ng8p0GE_S_mxSu9AZudataplRfAB8eABluJo-jHgI6H6NJHibUXLG-U0I2rEjZXuoyIGa_fnyGM73LTD_PrFjeP_3eo-FvSEVQ7QVoNl5fw5RTOdf_gX8AZF2gyw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Pardo, Scott</creator><creator>Dunne, Nancy</creator><creator>Simmons, David A.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170901</creationdate><title>Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems</title><author>Pardo, Scott ; Dunne, Nancy ; Simmons, David A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3495-bb12416acc407ab25f7963eb440014baebb84e0621a19bd976ca58acb85942163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Blood Glucose Self-Monitoring - adverse effects</topic><topic>Blood Glucose Self-Monitoring - methods</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Insulin - administration & dosage</topic><topic>Medication Errors - statistics & numerical data</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pardo, Scott</creatorcontrib><creatorcontrib>Dunne, Nancy</creatorcontrib><creatorcontrib>Simmons, David A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes science and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pardo, Scott</au><au>Dunne, Nancy</au><au>Simmons, David A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems</atitle><jtitle>Journal of diabetes science and technology</jtitle><addtitle>J Diabetes Sci Technol</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>11</volume><issue>5</issue><spage>970</spage><epage>974</epage><pages>970-974</pages><issn>1932-2968</issn><eissn>1932-2968</eissn><eissn>1932-3107</eissn><abstract>Background:
In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosing errors were compared for each trial.
Method:
For each blood glucose measurement, premeal bolus insulin dosing was determined for a hypothetical person, assuming a 60-g carbohydrate meal and 100-mg/dL target blood glucose level (adjusting 1/25 insulin sensitivity and 1/15 insulin:carbohydrate ratio inputs to account for BGMS measurement error). Dosing error was the difference between doses calculated using the BGMS and YSI results.
Results:
In Clinical Trial 1, 95% dose error ranges (in units of insulin) were: CONTOUR®NEXT EZ BGMS (EZ), –0.9 to 0.5; Accu-Chek® Aviva BGMS (ACA), –0.5 to 1.8; FreeStyle Freedom Lite® BGMS (FFL), –3.2 to −0.3; OneTouch® Ultra®2 BGMS (OTU2), –4.1 to 0.3; and Truetrack® BGMS (TT), –3.9 to 2.2. In Clinical Trial 2, these ranges were: CONTOUR®NEXT BGMS (CN), –0.7 to 1.7; Accu-Chek® Aviva Nano BGMS (ACAN), –1.3 to 1.8; FreeStyle Lite® BGMS (FSL), –5.1 to 0.2; OTU2, –1.9 to 1.2; OneTouch® Verio® Pro BGMS (OTVP), –1.0 to 1.9; and TT, –5.1 to 1.7. Within each trial, EZ and CN had statistically significantly smaller insulin dose error ranges than other BGMSs (P <0.0001).
Conclusions:
The ranges of insulin dose errors were statistically significantly smaller with EZ and CN than with all other BGMSs in this post hoc analysis. Differences in BGMS accuracy could result in clinically important differences in insulin dosing.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>28604064</pmid><doi>10.1177/1932296817713025</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-2968 |
| ispartof | Journal of diabetes science and technology, 2017-09, Vol.11 (5), p.970-974 |
| issn | 1932-2968 1932-2968 1932-3107 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5950998 |
| source | Access via SAGE; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Blood Glucose Self-Monitoring - adverse effects Blood Glucose Self-Monitoring - methods Clinical Trials as Topic Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 2 - blood Humans Hypoglycemic Agents - administration & dosage Insulin - administration & dosage Medication Errors - statistics & numerical data Original |
| title | Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A49%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bolus%20Insulin%20Dose%20Error%20Distributions%20Based%20on%20Results%20From%20Two%20Clinical%20Trials%20Comparing%20Blood%20Glucose%20Monitoring%20Systems&rft.jtitle=Journal%20of%20diabetes%20science%20and%20technology&rft.au=Pardo,%20Scott&rft.date=2017-09-01&rft.volume=11&rft.issue=5&rft.spage=970&rft.epage=974&rft.pages=970-974&rft.issn=1932-2968&rft.eissn=1932-2968&rft_id=info:doi/10.1177/1932296817713025&rft_dat=%3Cproquest_pubme%3E1908794630%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1908794630&rft_id=info:pmid/28604064&rft_sage_id=10.1177_1932296817713025&rfr_iscdi=true |